Q-omics provides the consensus-scored MIR30A profile across patient tissues and cancer cell-line models. MIR30A expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MIR30A is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, MIR30A RNA expression shows 10,801 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight BLCA, KIRC, and LUAD as cancer lineages where MIR30A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR30A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR30A survival associations across molecular data types. MIR30A RNA expression shows survival associations in the most cancer types (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR30A RNA expression–survival associations across cancer types. High MIR30A expression shows unfavorable associations in BLCA, KIRP, ESCA, LUSC, KIRC and UCEC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for MIR30A RNA expression.
This table summarizes MIR30A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR30A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR30A shows lower tumor expression in KIRC. The KIRC box plot shows higher MIR30A RNA expression in normal versus tumor tissue (log2 FC = −0.079, t-test p = .013).
This table shows molecular features associated with MIR30A in patient tissues and cancer cell lines. In patient samples, MIR30A shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
